RxDoctor Payments Data

Fausto Delacruz, MD

Internal Medicine · Pembroke Pines, FLNPI 1376535484

Payments from drug & device makers

$5,637in general payments, 2019–2025

Across 297 payments — averaging $18.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$805
  • Lilly USA, LLC$508
  • Pfizer$445
  • Otsuka America Pharmaceutical, Inc.$318
  • Mallinckrodt Hospital Products Inc.$300
  • Astellas Pharma US Inc$224
  • plus $3K from 39 others

What the payments were for

  • Food & beverage$5,57699%
  • Education$611%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,637 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$182,464
Medicare patients
291
Services billed
1,523

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban82$90,934
OzempicSemaglutide59$79,614
JardianceEmpagliflozin47$63,279
TradjentaLinagliptin39$38,178
MounjaroTirzepatide30$37,590
LinzessLinaclotide32$33,140
ProliaDenosumab17$29,320
TrulicityDulaglutide23$28,273
FarxigaDapagliflozin Propanediol28$27,900
XareltoRivaroxaban25$24,973
JanuviaSitagliptin Phosphate20$23,431
MyrbetriqMirabegron18$19,874
VascepaIcosapent Ethyl19$11,863
BrilintaTicagrelor12$10,905
JanumetSitagliptin Phos/Metformin Hcl13$9,488

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$183$101,45786 claims
PfizerEliquis, Paxlovid$445$92,29498 claims
Novo NordiskOzempic$805$79,61459 claims
Lilly USA, LLCMounjaro, Trulicity$508$65,86253 claims
AstraZenecaFarxiga, Brilinta, Symbicort$214$45,27955 claims
AbbVieLinzess, Synthroid$191$37,32365 claims
MerckJanuvia, Janumet$16$32,91933 claims
AmgenProlia$67$29,32017 claims
Johnson & JohnsonXarelto$192$24,97325 claims
Astellas Pharma US IncMyrbetriq$224$19,87418 claims
GSKBreo Ellipta$204$7,69319 claims
Sanofi-aventis U.S. LLCLantus$126$5,87615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Pembroke Pines

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →